. Introduction {#s01}
==============

In Japan, the recommendation of vaccination of human papillomavirus (HPV) by the Ministry of Health, Welfare, and Labor has been suspended, thus the number of patients with cervical cancer has increased in conjunction with lower receiving ratio of Pap smear test as 37.3%−42.3% in 2016 ([@b1]). Especially, the issues of uterine cervical cancer are not only the increase of the disease in adolescents and young adults generation (AYA generation) but also the percentage of adenocarcinoma of cervix which has been increased in comparison with that of squamous histology \[squamous cell carcinoma (SCC)\] ([@b2]). As for diagnosis in cervical adenocarcinoma, it is very difficult to detect in early stage by yearly screening of Pap smear test. Even if cervical adenocarcinoma is detected at earlier stages, it causes ovarian metastases more frequent than that of SCC ([@b3],[@b4]). Furthermore, because of its dependency on estrogen in proliferation, the treatment of cervical adenocarcinoma with fertility preservation in AYA generation has been restricted to very early stage such as IB1 stage with small volume disease. It is well known that cervical adenocarcinoma has been life-threatening disease because of its biologically malignant character, such as resistance to usual radiotherapy (RT) including concurrent chemoradiotherapy (CCRT) with cisplatin or systemic chemotherapy (CT) ([@b5],[@b6]). Cervical adenocarcinoma was not homogeneous as well, which consists of at least 5 subtypes, such as endometrioid type, endocervical type, mucinous intestinal type, adeno-squamous type and gastric morphology and immunophenotype, which is called "adenoma malignum" or "minimal deviated adenocarcinoma". The endometrioid type is sensitive for chemotherapy like corpus cancer, on the other hand, gastric type shows apparently poorer prognosis than that of other subtypes because of chemo-resistance ([@b7]). In Japan, 5 year-survival of SCC and adenocarcinoma of cervix showed 58.7% and 40.0% (P\<0.005, Kaplan-Meir, Tukey-Cremer analysis), respectively in stage III ([@b8]).

As for treatments for advanced cervical cancer, the efficacy of CCRT has been elucidated by many randomized trials in SCC ([@b9]-[@b13]), and it was endorsed by the National Cancer Institute (NCI)-recommendation of CCRT in patients with cervical cancer stage over IB2 ([@b14]).

To cure or control cervical adenocarcinomas was an urgent issue for us. To date, in spite of the improvement of CT or CCRT in SCC, survival superiority of the CT and CCRT in the treatment of cervical adenocarcinoma and endometrial cancer has not been identified. In order to improve the prognosis of advanced cervical adenocarcinoma and endometrial cancer, the new effective regimen of CCRT must be explored.

Iirinotecan hydrochloride (CPT-11) was considered as a good partner with CCRT, because of its sensitizing effect of irradiation ([@b15]-[@b20]). It is well known that CPT-11 is a semisynthetic analog of camptothecin, originally isolated from the ornamental tree *Camptotheca acuminata*. CPT-11 is transformed to an active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38) by carboxyl esterase which is mainly found in the liver, bowel mucosa, and tumor tissue ([@b21]), and plays an essential role in the cytocidal activity and toxicity of the parent compound ([@b22]). Irinotecan has been used for cervical cancer in Japan and its response rates of the disease were reported from 9.1% to 29.3% ([@b22],[@b23]). As for enhancing radio-sensitivity, fundamental experiment showed the elevation of sensitivity of irradiation *in vitro* for colorectal cancer ([@b17]). As for clinical use, the CCRT with irinotecan was reported to be useful in the treatment for advanced rectal cancer in CCRT setting ([@b24]). Thus, CPT-11 seems to become one of the candidates as an agent used for cervical cancer especially for cervical adenocarcinoma which showed resistance to CCRT with cisplatin. We conducted a phase 1/2 study for uterine cancers to determine the feasibility and MTD of concurrent use with irradiation in patients with uterine cancers (SCC, cervical adenocarcinoma, and endometrioid cancer).

. Materials and methods {#s02}
=======================

Study design {#s02.01}
------------

This study was prospective, exploring, non-randomized, interventional dose finding study and was registered in University Hospital Medical Information Network (UMIN) (No. UMIN000000148).

Radiotherapy was fixed as extra pelvic irradiation with/without high-dose rate brachytherapy for pelvic lesion and 45 Gy for para-aortic lesion. Dose of CPT-11 was escalated from 30 mg/m^2^ to 60 mg/m^2^ in 10 mg/m^2^ incremental dose, and the maximum tolerated dose (MTD) and recommended dose \[one dose level (DL) down of MTD\] was assessed by modified Fibonacci method. The study period was from Aug 1st, 2002 to Dec 31st, 2008.

This study was approved by institutional review board (IRB) of each institution in Kansai Clinical Oncology Group (KCOG), and written informed consent was obtained from each accrued patient. The study followed the current guidelines of the International Conference on Harmonization for good clinical practice and the Declaration of Helsinki.

. Patients and methods {#s02.02}
----------------------

Eligibility criteria were as follows: 1) unresectable advanced/recurrent uterine cancers (cervical cancer/endometrial cancer) that are pathologically diagnosed, adenocarcinoma was preferable. SCC and endometrioid cancer were also allowed because fully efficacy of this treatment had not been reported, and adverse events (AEs) would not be different between cervical adenocarcinoma and SCC because of the same radiation field and the same dose and dosage; 2) the disease must be measurable and the response must be evaluated according to the response criteria of solid tumor (RECIST) version 1.0; 3) regional lymph-nodes (and para-aortic nodes below 326b1) metastases are allowed as measurable lesions but no distal metastases in other organs (lung metastasis or brain metastasis, or distal lymph nodes upper than the 326b1) were required; 4) prior treatments were allowed except RT and/or CT by topoisomerase 1 inhibitor; 5) the interval of the prior therapy must be over 4 weeks (including with biological response modifier); 6) patient's age must be 20−75 years old at informed consent; 7) Eastern Cooperative Oncology Group (ECOG) performance status scores (PS) must be 0−2; 8) patients have a life expectancy greater than 3 months; and 9) no severe dysfunctions in major organs (bone mallow, heart, lung, liver, kidney) were necessary. All patients signed informed consent forms that were approved by the participating institution's IRB before screening.

Exclusive criteria were as follows: 1) patients who had received prior RT and the irradiation field would be overlapped; 2) patients who had other active progressive cancers, or active aggressive infection diseases, over grade 2 diarrhea, ileus, interstitial pneumonitis, massive ascites or pleural fluid retention; 3) patients who had been pregnant or were lactating were excluded for fear of teratogenicity or bone marrow suppression of baby due to placental transition or milk transfer of the SN-38, an active form of CPT-11; or 4) patients who had received CT with CPT-11 before or had hypersensitivity to CPT-11.

. Protocol treatment {#s02.03}
--------------------

### RT {#s02.03.01}

In pelvic region, RT was used external irradiation: Irradiation was delivered using 3-dimensional (3D)-conformal radiation (a dose of 45 Gy, 1.8 Gy × 25 fractions). Brachytherapy was used with high-dose rate, 6 Gy for 3 or 4 times by Remote After Loading System (RALS). In para-aortic region, RT was used as an additional treatment if there are metastases at para-aortic lesions. Para-aortic RT was the same dose of pelvic external irradiation at a dose of 45 Gy (1.8 Gy × 25 fractions) from upper plane of 12th thoracic bone to lower plane of 4th lumbar bone in 8 cm width with 4-field box technique.

### . CT {#s02.03.02}

CPT-11 (Yakult Honsha, Tokyo, Japan, and Daiichi-Pharm., Tokyo, Japan) was administered by intra venous administration via peripheral venous access once a week, during earlier period the week (from on Monday to winthin on Wednesday), for 4 times during irradiation (*[Figure 1](#Figure1){ref-type="fig"}*, *[Table 1](#Table1){ref-type="table"}*,*[2](#Table2){ref-type="table"}*). The agent was diluted into 250−500 mL of saline and administered in 90 min, on d 1, d 8, d 15, and d 22. Only one skip was allowed and if skipped one administration, additional one administration must be performed on d 29, during the period of external RT.

![Administration of CPT-11 must be performed early of week on Monday to on Wednesday. Schedule of chemotherapy: skipping 1 week will be allowed. If the administration is skipped once during the first 4 weeks, the last administration can be performed on the fifth week. CPT-11, irinotecan hydrochloride; \*, spare administration for prior skipped administration.](cjcr-32-2-218-1){#Figure1}

###### Criteria of skip of chemotherapy

  -----------------------------------------------------------------
  Variables                                Criteria
  ---------------------------------------- ------------------------
  ANC                                      More than 750/mm^3^

  Platelet                                 More than 75,000/mm^3^

  Infection and fever                      No fever (over 38.3°C\
                                           without infection)

  Diarrhea                                 Less than grade 1

  Other non-hematological adverse events   Less than grade 2
  -----------------------------------------------------------------

###### Discontinuation of radiotherapy

  Discontinuation               Resume
  ----------------------------- -----------------------
  ANC under 750/mm^3^           More than 500/mm^3^
  Platelet under 50,000/mm^3^   More than 5,000/mm^3^
  Diarrhea more than grade 2    Grade 1

Sequential two skips were dealt with as discontinuation of protocol treatment due to dose limiting toxicity (DLT). The starting DL of CPT-11 was 30 mg/m^2^ (DL1) given weekly for 4 weeks. Subsequently, dose escalation was scheduled in 10 mg/m^2^ increments to 60 mg/m^2^ (DL4). During the treatment of dose level 2 (DL2) in 2005, the pharmaceutical alert concerning to metabolic enzymes for SN-38 (metabolite from CPT-11 and having most anticancer bio-activity), uridine diphosphate glucuronosyltransferase 1A1 (*UGT1A1*) polymorphism, further 3 patients' cohort was added ([@b25]).

### . Supportive medication {#s02.03.03}

According to anti-emetic agents of the second levels of American Society of Clinical Oncology (ASCO) emetic guideline, that is, domperidone 10 mg t.i.d. per os and infusion of weak steroid as hydrocortisone sodium phosphate 200 mg/body with 100 mL of saline were used as pre-medication.

As for hematological toxicities, grade (G) 4 toxicity without absolute neutrophil counts (ANC) was dose limiting toxicity (DLT). In ANC, G4 and lasting 7 d were used as pre-medication.

Non-hematologically, any G4 toxicity and unknown G3 toxicity were regarded as DLTs. Especially, G3 diarrhea was regarded as DLT. Administration skip was performed if there was no recovery to G2 neutropenia, G2 thrombocytopenia, and G1 diarrhea from worse status.

Granulocyte-colony stimulating factor (GCSF) could be used according to ASCO guideline. Supportive treatments of anti-diarrhea including prophylactic use, such as loperamide and herbal medicine, hangeshashintou (Tsumura, Tokyo, Japan) could be allowed, but not intestinal alkalization.

### . Endpoints {#s02.03.04}

Primary endpoint was to decide the MTD of this treatment protocol according to modified Fibonacci method. The recommended dose was defined as one DL down of MTD. Secondary endpoints were detection of toxicity profiles, tumor-response rate (evaluated by RECIST version 1.0), progression-free survival (PFS) and overall survival (OS).

Safety was evaluated in all patients being received at least one course of the study by assessment of AEs, clinical laboratory test results, physical examinations, and vital signs. AEs and laboratory values were graded according to the NCI-CTC version 2.0. All patients were followed up until recovery from toxicity and OS was observed until relapse or progression of the disease.

. Statistical analysis {#s02.04}
----------------------

The toxicity profiles were assessed in frequency and severity in dose escalation manner and MTD was decided according to modified Fibonacci method. The response rate was calculated according to RECIST version 1.0. As for the survival analyses, the Kaplan-Meier method (log-rank test) with Greenwood's formula was used by SAS STATview 5.0 (SAS Institute Inc., Cary, USA). For the purpose of calculating OS, failure was defined as death of any cause. For the purpose of calculating disease-free survival (DFS, DFS is equal to PFS), the period from the date of obtaining informed consent to the date of the first appearance of loco-regional failure and/or distant failure of the disease was defined. All efficacy endpoints were measured from study entry to date of first failure or last follow-up visit for censored patient.

. Results {#s03}
=========

Patients' accrual diagram and results of Fibonacci are demonstrated in *[Figure 2](#Figure2){ref-type="fig"}*. *[Figure 2](#Figure2){ref-type="fig"}* demonstrates diagrams of overall accrual and result of DLT occurrence. Both DL1 and DL2 showed no DLT occurrence. During DL3, the second patient (DL3-2) showed DLTs (G3 diarrhea, G3 nausea, and G3 abdominal pain) and further three patients were accrual and they did not show any DLT. At DL4, first patient showed no DLTs. The second patient showed G3 abdominal pain and G3 diarrhea. The third patient showed G4 leukopenia and neutropenia lasting for more than 1 week. According to modified Fibonacci, the MTD was decided as DL4 60 mg/m^2^. Precise characteristics of patients are shown in *[Table 3](#Table3){ref-type="table"}*. The median age was 58 (range, 46−74) years old. At the third patient had accrued in DL1, further entry was halted until the third patient finished her protocol treatment and identified all adverse event at one month after of treatment. From DL2, the accrual patients number changed from 3 to 6 to identify the DLTs. Because, in 2005, pharmatheutical alert of CPT-11 concerning to polymorphism about*UGT1A1*was announced in United States, however, the invader assay had not available in Japan during this period, we could not evaluate the polymorphism of *UGT1A1*\*6 and/or \*28, so that double cohort system was used. As a result, there were no DLTs detected both in DL2 and DL3 patients. The 4th level (DL4) of dose patients, there was 2 DLTs out of 3 patients were detected and the MTD has decided as DL4 as 60 mg/m^2^.

![Diagrams of patients' accrual according to modified Fibonacci. Circle means patients with no DLT, and cross means patients with occurrence of DLT. DLT, dose limiting toxicity; DL, dose level.](cjcr-32-2-218-2){#Figure2}

###### Patients' accrual and characteristics

  Cases   Diagnosis             Age (year)   Histology/site of disease
  ------- --------------------- ------------ ---------------------------------
  DL1-1   Cervical recurrence   49           1b/ADC
  DL1-2   Cervical IVA          73           SCC
  DL1-3   Cervical IIB          55           SCC
  DL2-1   Cervical IIIB         67           ADC/T3N1M0
  DL2-2   Cervical IIIB         58           SCC
  DL2-3   Cervical IIIB         55           SCC
  DL2-4   Cervical recurrence   52           ADC/pT2bNR1M0, stump recurrence
  DL2-5   Cervical recurrence   46           SCC/pT2bNR1M0, PAN metastasis
  DL3-1   Cervical IIIB         61           ADC+SCC
  DL3-2   Cervical recurrence   69           SCC/lumber bone metastasis
  DL3-3   Cervical IB2          69           ADC
  DL3-4   Corpus recurrence     57           EMC, G3, PAN
  DL3-5   Cervical IVB          50           SCC, PAN
  DL3-6   Cervical recurrence   74           SCC, PAN
  DL4-1   Cervical recurrence   63           SCC, PAN
  DL4-2   Cervical IIIB         46           ADC, mucinous type
  DL4-3   Cervical IIB          72           SCC

Patients' clinical characteristics are shown in *[Table 3](#Table3){ref-type="table"}*. Among seventeen patients in total, adenocarcinoma occupied 7 (41.2%). All patients had unresectable and measurable bulky tumors and seven were recurrence.

. Toxicity and AEs {#s03.01}
------------------

As for hematologic toxicities, G3 and G4 neutropenia were detected in 3 patients (17.6%) and one G4 deserved as DLT in DL4. Grade 3 anemia was detected in 5 patients (29.4%) and no G3, G4 thrombocytopenia was detected. As for non-hematologic AEs, G3 diarrhea was detected in 2 patients (both 1 patient in DL3 and DL4) and both patients suffered from G3 abdominal pain at the same time. In total, 5 patients (29.4%) were detected as G2 diarrhea but they all recovered to G1 during secession of administration of CPT-11. As for nausea and vomiting, 5 patients complained over G1 nausea/vomiting, and 1 patient of DL3 needed admission and treatment (*[Table 4](#Table4){ref-type="table"}*). The evaluation of DLT demonstrated that one out of six patients was in DL3 (50 mg/m^2^), and two out of three in DL4 (60 mg/m^2^).

###### Toxicity profiles assessed by NCI-CTCAE version 3.0

  Grade                        0                1                   2                   3                  4   0   1   2   3       4   0   1   2   3   4   0   1   2   3   4
  ---------------------------- ---------------- ------------------- ------------------- ------------------ --- --- --- --- ------- --- --- --- --- --- --- --- --- --- --- ---
  Hematological toxicity       Leukopenia       Neutropenia         Anemia              Thrombocytopenia                                                                   
  DL1                          3                0                   0                   0                  0   3   0   0   0       0   1   2   0   0   0   3   0   0   0   0
  DL2                          2                1                   0                   0                  3   0   2   0   0       3   1   0   1   0   5   0   0   0   0   
  DL3                          2                0                   2                   1                  1   1   2   1   2       0   1   2   1   2   0   6   0   0   0   0
  DL4                          0                0                   1                   1                  1   0   0   2   0       1   0   0   1   2   0   3   0   0   0   0
  Non-hematological toxicity   Diarrhea         Nausea/Vomiting     Asthenia            Ileus                                                                              
  DL1                          3                0                   0                   0                  0   3   0   0   0       0   1   2   0   0   0   3   0   0   0   0
  DL2                          2                2                   1                   0                  0   4   0   1   0       0   5   0   0   0   0   4   1   0   0   0
  DL3                          0                3                   2                   1^\*^              0   2   1   1   1^\*^   0   5   0   1   0   0   6   0   0   0   0
  DL4                          0                0                   2                   1^\*^              0   3   0   0   0       0   1   2   0   0   0   2   0   1   0   0
  Non-hematological toxicity   Abdominal pain   Liver dysfunction   Renal dysfunction   Hypersensitivity                                                                   
  DL1                          3                0                   0                   0                  0   2   1   0   0       0   3   0   0   0   0   3   0   0   0   0
  DL2                          5                0                   0                   0                  0   3   2   0   0       0   5   0   0   0   0   5   0   0   0   0
  DL3                          3                2                   0                   1^\*^              0   3   3   0   0       0   6   0   0   0   0   6   0   0   0   0
  DL4                          1                0                   1                   1^\*^              0   3   0   0   0       0   3   0   0   0   0   3   0   0   0   0

. Responses of treatment {#s03.02}
------------------------

Responses shown in *[Table 5](#Table5){ref-type="table"}* are 9 complete response (CR) + 3 partial response (PR) + 3 stable diseases (SD)/17 (88.2%) in all cases. The result showed that no progressive disease (PD) was detected. Disease control rate which was defined as CR, PR, SD per total cases were 88.2%. 5/6 (83.3%) in adenocarcinoma, 10/11 (90.9%) in SCC. Local control was completed in higher than DL2 (40 mg/m^2^). Two cases of DL4 did not complete the protocol treatment and changed to RT alone, and they were not evaluable (NE) for response.

###### Response of treatment

  Cases   Histology   Response   Distant metastasis   PFS (month)   OS (month)   Outcome
  ------- ----------- ---------- -------------------- ------------- ------------ ---------
  DL1-1   ADC         SD         N                    5.6           21.6         DOD
  DL1-2   SCC         CR         N                    7.0           16.3         DOD
  DL1-3   SCC         CR         Virchow              3.1           19.4         AWD
  DL2-1   ADC         CR         N                    N/A           15.2         DOD
  DL2-2   SCC         CR         PAN                  3.5           56.4         AWD
  DL2-3   SCC         CR         Liver, PAN           5.4           7.4          DOD
  DL2-4   ADC         PR         N                    N/A           23.8         NED
  DL2-5   SCC         CR         N                    N/A           28.0         NED
  DL3-1   ADSQ        PR         Lung                 N/A           45.3         NED
  DL3-2   SCC         SD         Virchow              6.4           30.5         AWD
  DL3-3   ADC         CR         N                    N/A           38.2         NED
  DL3-4   EMC         SD         N                    N/A           7.8          AWD
  DL3-5   SCC         CR         N                    7.0           28.2         NED
  DL3-6   SCC         CR         N                    N/A           6.5          NED
  DL4-1   SCC         PR         N                    N/A           29.8         NED
  DL4-2   ADC         NE         N                    4.1           6.4          DOD
  DL4-3   SCC         NE         PAN                  3.5           10.1         AWD

Pelvic lesions of this case achieved CR (DL3-1) are shown in *[Figure 3A](#Figure3){ref-type="fig"}* (pre-treatment) and *[Figure 3B](#Figure3){ref-type="fig"}* (after one month of treatment completion).

![Case presentation of contrast enhanced-computed tomography (case DL3-1, stage IIIb, adenosquamous cell carcinoma). (A) Pre-treatment: pelvic lymph nodes metastases were seen (arrows); (B) Post-treatment after 2 months. No tumors were detected in the pelvis. DL, dose level.](cjcr-32-2-218-3){#Figure3}

The median progression-free survival (mPFS) time and overall survival (mOS) time were 6.7 \[95% confidence interval (95% CI): 6.1−16.8\] months and 29.4 (95% CI: 13.6−28.7) months, respectively. The Kaplan-Meier curves are shown in*[Figure 4A](#Figure4){ref-type="fig"}*,*[B](#Figure4){ref-type="fig"}*. Histological subtype stratification analyses demonstrate that SCC showed longer PFS than adenocarcinoma but there are not significant differences by log-rank method (*[Figure 4C](#Figure4){ref-type="fig"}*). There are no significant differences in OS (*[Figure 4D](#Figure4){ref-type="fig"}*).

![Survival rate of CCRT with CPT-11 (Kaplan-Meier Curve Log-rank test).(A) PFS of all cases, mPFS are 6.7 (95% CI: 6.1−16.8) months; (B) OS of all cases, mOS are 29.4 (95% CI: 13.6−28.7) months; (C) Differences between ADC and SCC in PFS. SCC cases were tendency of longer survivals but not significant (P=0.58); (D) No differences between ADC and SCC were seen in OS (P=0.65). CCRT, concurrent chemoradiotherapy; CPT-11, irinotecan hydrochloride; PFS, progression-free survival; mPFS, median PFS; 95% CI, 95% confidence interval; OS, overall survival; mOS, median OS; ADC, adenocarcinoma; SCC, squamous cell carcinoma.](cjcr-32-2-218-4){#Figure4}

. Discussion {#s04}
============

It is an important issue to control the progression of unresectable uterine cancer. SCC is relative sensitive to both CT and RT, but for cervical adenocarcinoma and endometrial cancer, no effective treatment was found in CT, RT, and combination of CT and RT including CCRT.

We conducted this phase 1/2 study of CCRT using CPT-11 to resolve such issue. As a result of our study, the concurrent setting of CPT-11 and external RT was safe and effective at a dose of 50 mg/m^2^ weekly administration for 4 or 5 weeks. The management of AE concerning diarrhea maybe necessary. We used herbal medicine, hangeshashintou (Tsumura, Tokyo, Japan) during irradiation period in prophylactic manner. Neutropenia was the second DLT of this protocol, but severe AE was not detected. This study was performed before checking rule according to *UGT1A1* polymorphism, single nucleoside polymorphism (SNP) in \*6 and \*28. The reports of *UGT1A1* SNPs had been emerging during the trial period, in over DL2, patients' accrual was modified from 3 patients to 6 patients in one cohort. As a result, in DL2, five patients out of six were feasible, then dose escalation was advanced to DL3. In DL3, one patient experienced G3 diarrhea, G3 nausea/vomiting, and G3 abdominal pain. They were all recovered without complications by secession of administration of CPT-11. Eventually, only one patient showed DLT out of six patients, then trial had moved on DL5. In DL5, two patients showed DLTs out of three patients, and the MTD was decided as DL5, 60 mg/m^2^. The AEs were G3 diarrhea and G3 abdominal pain in different patients.

This study was not a randomized study, so the case number was very small. Further analyses of stratifications such as the differences between SCC and adenocarcinoma had apparent biases, and it should be kept in mind as a reference, and of course, it was not statistically significant. Further study of randomized phase 2/3 in unresectable adenocarcinoma of uterus must be warranted.

The administration of CPT-11 must be early of the week because its active form of SN-38 concentration keeps effective level for three days due to re-uptake from intestine as so-called enterohepatic circulation. From this fact, some studies reported the effectiveness of twice administrations of a week of CPT-11 *in vivo* analyses using mice, but CPT-11 induces gastrointestinal toxicity including nausea/vomiting and anorexia. Twice a week administration would not be good for patients' quality of life.

From the pharmacokinetic point of view, alkalization of intestine did not decrease both concentration and area under the curve (AUC) ([@b26]). Reduction of diarrhea and neutropenia will be controlled by alkalization of intestine as well ([@b27]). However, the latter study was a retrospective study and there were no pharmacokinetic analyses and the relation of SN-38 AUC and neutropenia remains unclear. It must be elucidated the mechanism of reduction of neutropenia in prospective pharmacokinetic study. Actually, if two major AEs were suppressed, more escalation of CPT-11 dosage might be achieved and peripheral concentration and full-dose intensity (CPT-11 300 mg/m^2^/4 weeks) can be maintained.

In our study, CPT-11 plays a role of sensitizer in local irradiation area, and does not affect distal metastases. Actually, in this dose setting, systemic effect was not obtained, and recurrence at distal lesions had been detected in most of lower dose than MTD (60 mg/m^2^) (*[Table 4](#Table4){ref-type="table"}*). In order to eliminate the distal micro-metastases, it would be necessary to dose escalation up to 100 mg/m^2^ under fully prophylactic premedication intestinal alkalization or additional anti-cancer agents such as 5-fluorouracil (5-FU) or tegafur/gimeracil/oteracil (TS-1^R^).

As other combination with CCRT, paclitaxel and carboplatin had been reported that the combination showed better OS in adenocarcinoma than SCC, but the limitation of this study was that this study was retrospective, and the biases of patient numbers were limited ([@b28]).

. Conclusions {#s05}
=============

This phase 1/2 study of CCRT using CPT-11 was feasible and effective in this cohort of patient. The recommended dose was 50 mg/m^2^ weekly administration for 4 times during irradiation period. Further prospective randomized phase 2/3 study using CCRT with cisplatin, CCRT with paclitaxel/carboplatin doublet and CCRT with CPT-11 might be mandatory. Secondly, P1 dose escalation study using intestinal alkalization should be conducted concomitant with *UGT1A1* SNP examination.
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